Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Intercept Pharmaceuticals stock | $16.63
Learn how to easily invest in Intercept Pharmaceuticals stock.
Intercept Pharmaceuticals, Inc is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Intercept Pharmaceuticals employs 498 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Intercept Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ICPT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Intercept Pharmaceuticals stock price (NASDAQ: ICPT)Use our graph to track the performance of ICPT stocks over time.
Intercept Pharmaceuticals shares at a glance
|Latest market close||$16.63|
|52-week range||$13.88 - $55.59|
|50-day moving average||$19.22|
|200-day moving average||$22.74|
|Wall St. target price||$34.81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-10.44|
Buy Intercept Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Intercept Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intercept Pharmaceuticals price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-16.81%|
|3 months (2021-05-03)||-16.64%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Intercept Pharmaceuticals financials
|Revenue TTM||$321.7 million|
|Gross profit TTM||$307.4 million|
|Return on assets TTM||-17.16%|
|Return on equity TTM||-143254.91%|
|Market capitalisation||$571.7 million|
TTM: trailing 12 months
Shorting Intercept Pharmaceuticals shares
There are currently 5.1 million Intercept Pharmaceuticals shares held short by investors – that's known as Intercept Pharmaceuticals's "short interest". This figure is 11.4% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Intercept Pharmaceuticals shares can be evaluated.
Intercept Pharmaceuticals's "short interest ratio" (SIR)
Intercept Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Intercept Pharmaceuticals shares currently shorted divided by the average quantity of Intercept Pharmaceuticals shares traded daily (recently around 564848.54910714). Intercept Pharmaceuticals's SIR currently stands at 8.96. In other words for every 100,000 Intercept Pharmaceuticals shares traded daily on the market, roughly 8960 shares are currently held short.
However Intercept Pharmaceuticals's short interest can also be evaluated against the total number of Intercept Pharmaceuticals shares, or, against the total number of tradable Intercept Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intercept Pharmaceuticals's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Intercept Pharmaceuticals shares in existence, roughly 150 shares are currently held short) or 0.1755% of the tradable shares (for every 100,000 tradable Intercept Pharmaceuticals shares, roughly 176 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intercept Pharmaceuticals.
Find out more about how you can short Intercept Pharmaceuticals stock.
Intercept Pharmaceuticals share dividends
We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.
Intercept Pharmaceuticals share price volatility
Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $13.88 up to $55.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 1.5511. This would suggest that Intercept Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intercept Pharmaceuticals overview
Intercept Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors.
Stocks similar to Intercept Pharmaceuticals
Intercept Pharmaceuticals in the news
Intercept price target raised to $22 from $18 at B. Riley
Intercept price target lowered to $67 from $74 at Wedbush
Intercept price target lowered to $18 from $21 at H.C. Wainwright
Frequently asked questionsWhat percentage of Intercept Pharmaceuticals is owned by insiders or institutions?
Currently 15.526% of Intercept Pharmaceuticals shares are held by insiders and 76.437% by institutions. How many people work for Intercept Pharmaceuticals?
Latest data suggests 498 work at Intercept Pharmaceuticals. When does the fiscal year end for Intercept Pharmaceuticals?
Intercept Pharmaceuticals's fiscal year ends in December. Where is Intercept Pharmaceuticals based?
Intercept Pharmaceuticals's address is: 10 Hudson Yards, New York, NY, United States, 10001 What is Intercept Pharmaceuticals's ISIN number?
Intercept Pharmaceuticals's international securities identification number is: US45845P1084 What is Intercept Pharmaceuticals's CUSIP number?
Intercept Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 45845P108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert